Direct Angio Suite Acute Stroke Intervention With CT/DSA Hybrid Emergency Stroke Unit
Starting soon · Phase 3
Conditions studied: Acute Ischemic Stroke, Large Vessel Occlusion
In brief
This study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic stroke who are eligible for endovascular thrombectomy within 24 hours of symptom onset will be enrolled. Participants will be randomly assigned to one of two groups. In the intervention group, participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images. In the control group, participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT. The primary endpoint is puncture-to-successful-reperfusion time (PRT); if successful reperfusion is not achieved, the end-of-procedure time will be used.
Key facts
- Study ID
- NCT07670065
- Run by
- Beijing Tiantan Hospital
- People needed
- 232
- Starts
- 2026-06-08
- Expected to finish
- 2027-10-15
- Last updated by the study team
- 2026-06-26
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-60 years;
- Clinical diagnosis of acute ischemic stroke eligible for immediate endovascular treatment;
- Time from symptom onset or last known well ≤ 24 hours;
- Intravenous intracranial and cervical CT angiography completed;
- Confirmed target vessel occlusion amenable to endovascular intervention based on intravenous intracranial and cervical CT angiography findings;
- Written informed consent obtained from the patient or their legally authorized representative.
You may not qualify if…
- Known contrast agent allergy;
- Renal insufficiency with GFR (glomerular filtration rate) < 45 mL/min/1.73 m²;
- History of kidney transplantation;
- Concomitant diabetes mellitus with current use of metformin;
- Women who are pregnant, breastfeeding, or have a positive pregnancy test at admission;
- Refractory hypertension (defined as systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) (Note: patients may be enrolled if blood pressure is successfully reduced and maintained at an acceptable level with antihypertensive therapy);
- Intracranial space-occupying lesion or other conditions deemed unsuitable for endovascular intervention on imaging;
- Any other serious comorbidity or complication that may interfere with study conduct or evaluation.
Where it is running
- Beijing Tiantan Hospital — Beijing, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.